TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 2:14 · GLP-1 & Metabolic Drugs · GLP-1 & Metabolic Drugs · FDA compounding pathway opens for therapeutic peptides beyond GLP-1s
episode briefing
Asymmetric Investing

Hims Peptide Catalyst: The Valuation Shift Nobody Saw Coming

2026-07-23 · 2 company · 6 thematic
sentiment
2 bull0 bear0 neu
speakers
travis hoium

Travis Hoium hosts the Asymmetric Investing podcast/YouTube channel and manages the Asymmetric portfolio. He conducts fundamental research using Fiscal AI and focuses on platform business models, healthcare technology, and consumer subscription businesses. He discloses holding Hims & Hers as one of his largest positions.

travis holly

Travis Holly runs Asymmetric Investing, a subscription newsletter and portfolio service where he buys stocks monthly. Hims & Hers is the largest position in the Asymmetric portfolio, which he claims has beaten the market.

now playing · GLP-1 & Metabolic Drugs · GLP-1 & Metabolic Drugs
Healthcare Systems & Policytailwindscore 6/10travis holly
Compounding pharmacy regulatory shift enables direct-to-consumer peptide access
The FDA's review of peptide compounding eligibility represents a structural policy shift that could legitimize direct-to-consumer peptide therapies outside traditional insurance reimburseme…
GLP-1 & Metabolic Drugstailwindscore 7/10travis holly
FDA compounding pathway opens for therapeutic peptides beyond GLP-1s
FDA advisory panel recommendations to allow compounding of peptides like BPC-157 and KPV create a new regulatory pathway for affordable peptide therapies, enabling platforms like Hims & Her…
GLP-1 & Metabolic Drugstailwindscore 7/10travis hoium
FDA peptide panel opens door for compounded BPC-157 and KPV
An FDA advisory panel voted 8-6 to recommend adding BPC-157 and KPV to the compounding list, creating a regulatory pathway for telehealth platforms like Hims & Hers to offer low-cost peptid…
AI in Healthcaretailwindscore 6/10travis holly
Hims & Hers builds AI-driven personalized care flywheel from lab data
Hims & Hers is shifting from transactional prescriptions to an AI-powered platform where lab data feeds conversational AI and providers to create personalized, compounded treatment plans wi…
AI in Healthcaretailwindscore 7/10travis hoium
Hims & Hers building AI-driven personalized care flywheel
The company is shifting from single-condition prescriptions to a comprehensive platform where lab data feeds conversational AI and providers to create personalized, compounded treatment sta…
Healthcare Systems & Policymixedscore 6/10travis hoium
Compounding regulatory shift creates asymmetric opportunity for telehealth
The end of GLP-1 compounding exemptions in Q1 2025 created a near-term headwind, but new FDA peptide recommendations could restore and expand the compounding model, giving platforms with in…